Piper Sandler Cuts Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $32.00

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective lowered by Piper Sandler from $36.00 to $32.00 in a report published on Friday,Benzinga reports. The firm currently has a neutral rating on the stock.

Separately, Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $28.29 on Friday. The business’s fifty day moving average is $31.91 and its two-hundred day moving average is $40.48. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a market cap of $1.35 billion, a P/E ratio of 9.43, a P/E/G ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals has a 52 week low of $25.89 and a 52 week high of $53.96.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $38,000. Voloridge Investment Management LLC increased its stake in Amphastar Pharmaceuticals by 16.2% during the 4th quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company’s stock worth $5,326,000 after purchasing an additional 19,991 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Amphastar Pharmaceuticals by 208.0% during the 4th quarter. Squarepoint Ops LLC now owns 17,664 shares of the company’s stock worth $656,000 after buying an additional 11,929 shares during the period. Twinbeech Capital LP bought a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $1,738,000. Finally, Systematic Financial Management LP acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $9,147,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.